Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Priyabrata Mukherjee and Resham Bhattacharya.
Priyabrata Mukherjee
Connection Strength
9.618
Resham Bhattacharya
  1. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 01; 69(23):9090-5.
    View in: PubMed
    Score: 0.349
  2. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66.
    View in: PubMed
    Score: 0.327
  3. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev. 2008 Aug 17; 60(11):1289-1306.
    View in: PubMed
    Score: 0.312
  4. Evaluation of I-TAC as a potential early plasma marker to differentiate between critical and non-critical COVID-19. Cell Stress. 2022 Jan; 6(1):6-16.
    View in: PubMed
    Score: 0.202
  5. Revealing macropinocytosis using nanoparticles. Mol Aspects Med. 2022 02; 83:100993.
    View in: PubMed
    Score: 0.196
  6. Small Non-Coding-RNA in Gynecological Malignancies. Cancers (Basel). 2021 Mar 03; 13(5).
    View in: PubMed
    Score: 0.191
  7. Hybrid Nanosystems for Biomedical Applications. ACS Nano. 2021 02 23; 15(2):2099-2142.
    View in: PubMed
    Score: 0.190
  8. Experimental conditions influence the formation and composition of the corona around gold nanoparticles. Cancer Nanotechnol. 2021; 12(1):1.
    View in: PubMed
    Score: 0.189
  9. When the chains do not break: the role of USP10 in physiology and pathology. Cell Death Dis. 2020 12 04; 11(12):1033.
    View in: PubMed
    Score: 0.188
  10. Gold nanoparticles inhibit activation of cancer-associated fibroblasts by disrupting communication from tumor and microenvironmental cells. Bioact Mater. 2021 Feb; 6(2):326-332.
    View in: PubMed
    Score: 0.184
  11. MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020 10 05; 21(10):e48483.
    View in: PubMed
    Score: 0.184
  12. Targeting the TGFß pathway in uterine carcinosarcoma. Cell Stress. 2020 Aug 25; 4(11):252-260.
    View in: PubMed
    Score: 0.184
  13. Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome. Sci Adv. 2020 07; 6(30):eaba5379.
    View in: PubMed
    Score: 0.183
  14. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer. FASEB J. 2020 09; 34(9):12024-12039.
    View in: PubMed
    Score: 0.183
  15. Cystathione ß-synthase regulates HIF-1a stability through persulfidation of PHD2. Sci Adv. 2020 07; 6(27).
    View in: PubMed
    Score: 0.182
  16. Cystathionine beta synthase regulates mitochondrial dynamics and function in endothelial cells. FASEB J. 2020 07; 34(7):9372-9392.
    View in: PubMed
    Score: 0.181
  17. Analysing the nanoparticle-protein corona for potential molecular target identification. J Control Release. 2020 06 10; 322:122-136.
    View in: PubMed
    Score: 0.178
  18. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. Int J Nanomedicine. 2020; 15:991-1003.
    View in: PubMed
    Score: 0.177
  19. KRCC1: A potential therapeutic target in ovarian cancer. FASEB J. 2020 02; 34(2):2287-2300.
    View in: PubMed
    Score: 0.176
  20. Hydrogen sulfide signaling in mitochondria and disease. FASEB J. 2019 12; 33(12):13098-13125.
    View in: PubMed
    Score: 0.174
  21. Nanoparticle Interactions with the Tumor Microenvironment. Bioconjug Chem. 2019 09 18; 30(9):2247-2263.
    View in: PubMed
    Score: 0.172
  22. Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine. Cell Stress. 2019 Jul 31; 3(8):267-279.
    View in: PubMed
    Score: 0.171
  23. Gold Nanoparticle Transforms Activated Cancer-Associated Fibroblasts to Quiescence. ACS Appl Mater Interfaces. 2019 Jul 24; 11(29):26060-26068.
    View in: PubMed
    Score: 0.170
  24. Gold Nanoparticles Disrupt Tumor Microenvironment - Endothelial Cell Cross Talk To Inhibit Angiogenic Phenotypes in Vitro. Bioconjug Chem. 2019 06 19; 30(6):1724-1733.
    View in: PubMed
    Score: 0.169
  25. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018 10; 17(10):2136-2143.
    View in: PubMed
    Score: 0.159
  26. Probing Cellular Processes Using Engineered Nanoparticles. Bioconjug Chem. 2018 06 20; 29(6):1793-1808.
    View in: PubMed
    Score: 0.157
  27. Cystathionine ß-synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB J. 2018 08; 32(8):4145-4157.
    View in: PubMed
    Score: 0.155
  28. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
    View in: PubMed
    Score: 0.152
  29. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.147
  30. BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56.
    View in: PubMed
    Score: 0.145
  31. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano. 2016 12 27; 10(12):10636-10651.
    View in: PubMed
    Score: 0.141
  32. Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 12; 30(12):4042-4055.
    View in: PubMed
    Score: 0.140
  33. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 08; 1859(8):983-93.
    View in: PubMed
    Score: 0.138
  34. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.135
  35. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy. 2016; 12(4):659-70.
    View in: PubMed
    Score: 0.133
  36. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84.
    View in: PubMed
    Score: 0.132
  37. Cystathionine ß-synthase regulates endothelial function via protein S-sulfhydration. FASEB J. 2016 Jan; 30(1):441-56.
    View in: PubMed
    Score: 0.131
  38. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65.
    View in: PubMed
    Score: 0.121
  39. Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem. 2014 Jun 18; 25(6):1078-90.
    View in: PubMed
    Score: 0.119
  40. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
    View in: PubMed
    Score: 0.115
  41. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013 Jun 14; 288(24):17610-8.
    View in: PubMed
    Score: 0.111
  42. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6700-5.
    View in: PubMed
    Score: 0.110
  43. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One. 2013; 8(3):e57522.
    View in: PubMed
    Score: 0.110
  44. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One. 2012; 7(3):e33650.
    View in: PubMed
    Score: 0.103
  45. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012 Apr 07; 41(7):2943-70.
    View in: PubMed
    Score: 0.102
  46. Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem. 2011 Dec; 11(10):965-73.
    View in: PubMed
    Score: 0.101
  47. Switching the targeting pathways of a therapeutic antibody by nanodesign. Angew Chem Int Ed Engl. 2012 Feb 13; 51(7):1563-7.
    View in: PubMed
    Score: 0.101
  48. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater. 2011 Nov 16; 23(43):5034-8.
    View in: PubMed
    Score: 0.099
  49. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011; 6(9):e24374.
    View in: PubMed
    Score: 0.099
  50. A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. Chem Commun (Camb). 2011 Aug 14; 47(30):8530-2.
    View in: PubMed
    Score: 0.098
  51. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 2011; 6(6):e20347.
    View in: PubMed
    Score: 0.098
  52. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.
    View in: PubMed
    Score: 0.096
  53. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine. 2011 Oct; 7(5):580-7.
    View in: PubMed
    Score: 0.095
  54. A core-shell nanomaterial with endogenous therapeutic and diagnostic functions. Cancer Nanotechnol. 2010 Dec 01; 1(1):13-18.
    View in: PubMed
    Score: 0.094
  55. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011 Feb; 28(2):237-59.
    View in: PubMed
    Score: 0.094
  56. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14541-6.
    View in: PubMed
    Score: 0.092
  57. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010 Jul 14; 10(7):2543-8.
    View in: PubMed
    Score: 0.091
  58. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv. 2010 Jun; 7(6):753-63.
    View in: PubMed
    Score: 0.091
  59. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J Mater Chem. 2010 Jan 01; 20(3):547-554.
    View in: PubMed
    Score: 0.088
  60. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010 Mar 08; 62(3):346-61.
    View in: PubMed
    Score: 0.087
  61. Protein-mediated autoreduction of gold salts to gold nanoparticles. Biomed Mater. 2008 Sep; 3(3):034105.
    View in: PubMed
    Score: 0.080
  62. Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal. 2008 Mar 31; 3:8.
    View in: PubMed
    Score: 0.078
  63. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology. 2007 May 08; 5:4.
    View in: PubMed
    Score: 0.073
  64. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J. 2005 Oct; 19(12):1692-4.
    View in: PubMed
    Score: 0.065
  65. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem. 2005 Aug 12; 280(32):28848-51.
    View in: PubMed
    Score: 0.064
  66. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005 May 01; 11(9):3530-4.
    View in: PubMed
    Score: 0.064
  67. Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers (Basel). 2021 Dec 15; 13(24).
    View in: PubMed
    Score: 0.050
  68. Corrigendum: Cystathionine ß-Synthase Is Necessary for Axis Development in vivo. Front Cell Dev Biol. 2018; 6:121.
    View in: PubMed
    Score: 0.040
  69. Cystathionine ß-Synthase Is Necessary for Axis Development in Vivo. Front Cell Dev Biol. 2018; 6:14.
    View in: PubMed
    Score: 0.039
  70. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008 Mar 15; 68(6):1970-8.
    View in: PubMed
    Score: 0.019
  71. Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology. 2008 Jan 30; 6:2.
    View in: PubMed
    Score: 0.019
  72. Lanthanide phosphate nanorods as inorganic fluorescent labels in cell biology research. Clin Chem. 2007 Nov; 53(11):2029-31.
    View in: PubMed
    Score: 0.019
  73. Inorganic phosphate nanorods are a novel fluorescent label in cell biology. J Nanobiotechnology. 2006 Oct 30; 4:11.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.